Variability in infection control measures for the percutaneous lead among programs implanting long-term ventricular assist devices in the United States

Progress in Transplantation

Volumn 22, Issue 4, 2012, Pages 351-359

  Cannon, Anne ^a   Elliott, Tonya ^b   Ballew, Carole ^c   Cavey, Julie ^d   O'Shea, Genevieve ^e   Franzwa, Jennifer ^f   Puhlman, Mark ^g   Bennett, Jami ^h   Ryan, Timothy ⁱ   Lockard, Kathleen ^e   Avrahami, Neshama ^j   Brennan, Pamela ^k   Kurien, Sudha ^l   Andrus, Shauna ^m   Dick, Sara ⁿ   Davis, Erin ⁿ  

^a UNIVERSITY OF COLORADO HOSPITAL   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d ST LUKE S MEDICAL CENTER   (United States)

^e PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g Providence Heart and Vascular Institute   (United States)

^h CHRISTUS Transplant Institute   (United States)

ⁱ UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^j NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^k TAMPA GENERAL HOSPITAL   (United States)

^l ADVOCATE CHRIST MEDICAL CENTER   (United States)

^m UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

ⁿ UNIVERSITY OF UTAH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC PROPHYLAXIS; ARTICLE; BANDAGE; BIOFILM; HEART ASSIST DEVICE; HUMAN; HYGIENE; IMMUNOCOMPROMISED PATIENT; INFECTION; INFECTION CONTROL; METHODOLOGY; QUESTIONNAIRE; RISK FACTOR; SUTURING METHOD; UNITED STATES;

ANTIBIOTIC PROPHYLAXIS; BANDAGES; BIOFILMS; HEART-ASSIST DEVICES; HUMANS; HYGIENE; IMMUNOCOMPROMISED HOST; INFECTION CONTROL; PROSTHESIS-RELATED INFECTIONS; QUESTIONNAIRES; RISK FACTORS; SUTURE TECHNIQUES; UNITED STATES;

EID: 84870472533     PISSN: 15269248     EISSN: None     Source Type: Journal    
DOI: 10.7182/pit2012612     Document Type: Article

References (54)

1. Zierer A, Melby SJ, Voeller RK, et al. Late onset driveline infections: the Achilles heel of prolonged left ventricular assist device support. Ann Thorac Surg. 2077;84:515-521.
2. Organ Procurement and Transplant Network. Data 2009-2010. http://optn.transplant.hrsa.gov/latestData/rptData.asp. Accessed February 17, 2012.
3. Stevenson L, Rose E. Left ventricular assist devices. Circulation. 2003;108:3059-3063.
4. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345:1435-1443.
5. Rogers JG, Aaronson KD, Boyle AJ, et al. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol. 2010;55:1826-1834.
6. Clegg A, Scott DA, Loveman E, Colquitt JL, Royle P, Bryant J. Clinical and cost-effectiveness of left ventricular assist device as a bridge to heart transplantation for people with endstage heart failure: a systematic review and economic evaluation. Eur Heart J. 2006;27:2929-2938.
7. Medicare National Coverage Determinations Manual, Section 20.9: Artificial Hearts and Related Devices. http://www.cms .gov/transmittals/ downloads/R2NCD1.pdf. Accessed February 17, 2012.
8. Oz MC, Gelijns A, Miller L, et al. Left ventricular assist devices as permanent heart failure therapy: the price of progress. Ann Surg. 2003;238:577-583.
9. Miller L, Nelson K, Bostic R, Tong K, Slaughter M, Long J. Hospital costs for left ventricular assist devices for destination therapy: lower costs for implantation in the post-REMATCH era. J Heart Lung Transplant. 2006;25:778-784.
10. Gordon RJ, Quagliarello B, Lowy FD. Ventricular assist devicerelated infections. Lancet Infect Dis. 2006;6(7):426-437.
11. Topkara V, Kondareddy S, Malik F, et al. Infectious complications in patients with left ventricular assist device: etiology and outcomes in the continuous-flow era. Ann Thorac Surg. 2010;90(4):1270-1277.
12. Chinn R, Dembitsky W, Eaton L, et al. Multicenter experience: prevention and management of left ventricular assist device infections. ASAIO J. 2005;51(4):461-470.
13. Aslam S, Hernandez M, Thornby J, Zeluff B, Darouiche RO. Risk factors and outcomes of fungal ventricular-assist device infections. Clin Infect Dis. 2010;50(5):664-671.
14. Monkowski DH, Axelrod P, Fekete T, Hollander T, Furukawa S, Samuel R. Infections associated with ventricular assist devices: epidemiology and effect on prognosis after transplantation. Transpl Infect Dis. 2007;9(2):114-120.
15. Bentz B, Hupcey J, Polomano R, Boehmer J. A retrospective study of left ventricular assist device infections. J Cardiovasc Manag. 2004;15(1):9-16.
16. Genovese EA, Dew MA, Teuteberg J, et al. Incidence and patterns of adverse event onset during the first 60 days after ventricular assist device implantation. Ann Thorac Surg. 2009;88: 1162-1170.
17. Topkara VK, Dang NC, Martens TP, et al. Effect of diabetes on short-and long-term outcomes after left ventricular assist device implantation. J Heart Lung Transplant. 2005;24:2048-2053.
18. Kirklin J, Naftiel D, Kormos R, et al. Second INTERMACS annual report. J Heart Lung Transplant. 2010;29(1):1-10.
19. Interagency Registry for Mechanical Assisted Circulatory Support. http://www.intermacs.org. Accessed June 19, 2012.
20. Holdy K, Dembitsky W, Eaton L, et al. Nutrition assessment and management of left ventricular assist device patients. J Heart Lung Transplant. 2005;24:1690-1696.
21. Raymond AL, Kfoury AG, Bishop CJ, et al. Obesity and left ventricular assist device driveline exit site infection. ASAIO J. 2010;56:57-60.
22. Coyle LA, Ising MS, Gallagher C, et al. Destination therapy: one-year outcomes in patients with a body mass index greater than 30. Artif Organs. 2010;34:93-97.
23. Heartmate XVE LVAS: Guidelines for Successful Outcomes. 2003. Thoratec Corporation. http://www.thoratec.com/-assets/download-tracker/H053-0403-ENGLISH. pdf. Accessed February 17, 2012.
24. Slaughter M, Pagani F, Rogers J, et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant. 2010;29(4 suppl):S1-S39.
25. Ankersmit HJ, Edwards NM, Schuster M, et al. Quantitative changes in T-cell populations after left ventricular assist device implantation: relationship to T-cell apoptosis and soluble CD95. Circulation. 1999;100:211-215.
26. Ankersmit HJ, Tugulea S, Spainer T, et al. Activation-induced T-cell death and immune dysfunction after implantation of leftventricular assist device. Lancet. 1999;354(9178):550-555.
27. Suvas S. Advancing age and immune cell dysfunction: is it reversible or not? Expert Opin Biol Ther. 2008;8:657-668.
28. Crameri R, Blaser K. Allergy and immunity to fungal infections and colonization. Eur Respir J. 2002;19:151-157.
29. Linton P, Thoman ML. T cell senescence. Front Biosci. 2001; 6:D248-261.
30. Bagdasarian NG, Malani AN, Pagani FD, Malani PN. Fungemia associated with left ventricular assist device support. J Card Surg. 2009;24:763-765.
31. Nurozler F, Argenziano M, Oz MC, Naka Y. Fungal left ventricular assist device endocarditis. Ann Thorac Surg. 2001;71: 614-618.
32. Goldberg SP, Baddley JW, Aaron MF, Pappas PG, Holman WL. Fungal infections in ventricular assist devices. ASAIO J. 2000;46:S37-S40.
33. John R, Kamdar F, Liao K, Colvin-Adams M, Boyle A, Joyce L. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridgeto-transplant therapy. Ann Thorac Surg. 2008;86(4):1227-1234.
34. Malani P, Dyke D, Pagani F, Chenoweth C. Nosocomial infections in left ventricular assist device recipients. Clin Infect Dis. 2002;34:1295-1300.
35. Martin SI, Wellington L, Stevenson KB, et al. Effect of body mass index and device type on infection in left ventricular assist device support beyond 30 days. Interact CardioVasc Thorac Surg. 2010;11:20-23.
36. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284: 1318-1322.
37. Toba FA, Akashi H, Arrecubieta C, Lowy FD. Role of biofilm in Staphylococcus aureus and Staphylococcus epidermidis ventricular assist device driveline infections. J Thorac Cardiovasc Surg. 2011;141(5):1259-1264.
38. Laupland KB, Conly JM. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. Clin Infect Dis. 2003; 37:933-938.
39. Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 2002;346:1871-1877.
40. Society of Thoracic Surgeons Workforce on Evidence Based Surgery. Antibiotic Prophylaxis in Cardiac Surgery. Part 1: Duration of Prophylaxis. Chicago, IL: Society of Thoracic Surgeons; 2005.
41. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection: Hospital Infection Control Practices Advisory Committee 1999. Infect Control Hosp Epidemiol. 1999;20:250-278.
42. Garey KW, Dao T, Chen H, et al. Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. J Antimicrob Chemother. 2006;58:645-650.
43. Schaffer J, Allen JG, Weiss ES, et al. Infectious complications after pulsatile-flow and continuous-flow left ventricular assist device implantation. J Heart Lung Transplant. 2011;30:164-171.
44. Tsukui H, Teuteberg JJ, Murali S, et al. Biventricular assist device utilization for patients with morbid congestive heart failure: a justifiable strategy. Circulation. 2005;112:I65-I72.
45. Hendry P. Invited commentary. Ann Thorac Surg. 2007;84: 520-521.
46. Holman W, Pamboukian S, Blood M, Tallaj J, McGiffin D, Kirklin J. Managing device infections: are we progressing or is infection an insurmountable obstacle? ASAIO J. 2005;51:452-455.
47. Schulman AR, Martens TP, Christos PJ, et al. Comparisons of infection complications between continuous flow and pulsatile flow left ventricular assist devices. J Thorac Cardiovasc Surg. 2007;133:841-842.
48. Pae WE, Connell JM, Adelowo A, et al. Does total implantability reduce infection with the use of a left ventricular assist device? The LionHeart experience in Europe. J Heart Lung Transplant. 2007;26:219-229.
49. Pagani FD, Miller LW, Russell SD, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol. 2009;5:312-321.
50. Siegenthaler MP, Martin J, Pernice K, et al. The Jarvik 2000 is associated with less infection than the HeartMate left ventricular assist device. Eur J Cardiothorac Surg. 2003;23:748-754.
51. Akhter S, Valeroso T, Pisarski B, et al. Technique of Heart-Mate II percutaneous lead externalization is associated with incidence of infection. J Heart Lung Transplant. 2011;29(4 suppl):S46.
52. Ledford ID, Miller DV, Mason NO, et al. Differential infection rates between velour versus silicone interface at the Heart-Mate II driveline exit site: structural and ultrastructural insight into possible causes. J Heart Lung Transplant. 2011;29:S10-11.
53. Tatooles AF, Gallagher CT, Pappas PS, Bresticker MA. Avoiding driveline infections in patients with left ventricular assist devices. J Heart Lung Transplant. 2011;29:S44.
54. Hannan MM, Husain S, Mattner F, et al. Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. J Heart Lung Transplant. 2011; 30:703-706.